However, dysregulation of the PI3K/AKT/mTOR pathway is widely reported among BC cell subtypes, suggesting that there may be a window of opportunity for administration of Eve in BC, independent of the biological subtype [24]. The gene discussed is MTOR; the disease is breast cancer.